Johnson & Johnson
JNJ
$231.29
+1.27%
Johnson & Johnson is the world's largest and most diverse healthcare firm, operating through two core divisions: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). As a global healthcare titan, it is a market leader and Dividend King, distinguished by its massive scale, diversified revenue streams, and a century-long commitment to innovation and shareholder returns. The current investor narrative is dominated by the company's post-Kenvue transformation into a pure-play healthcare entity, with intense focus on its ability to drive growth from its core immunology, oncology, and neurology franchises while navigating the looming patent expiration of its blockbuster drug Stelara, as evidenced by recent strategic acquisitions like Firefly Bio to bolster its oncology pipeline.…
JNJ
Johnson & Johnson
$231.29
Related headlines
Investment Opinion: Should I buy JNJ Today?
Rating & Thesis: Hold. Johnson & Johnson is a high-quality, defensive cornerstone holding currently in a transitional phase; the stock is fairly valued, offering a balanced risk/reward profile as it works to offset patent expirations with new growth drivers. This aligns with the mixed but generally positive analyst sentiment (e.g., RBC 'Outperform', HSBC 'Buy') and the implied valuation from forward EPS estimates.
Supporting Evidence: The stock trades at a forward P/E of 17.96x, which is reasonable for a company of its caliber and below its own historical peaks. It generates immense free cash flow ($19.7B TTM) supporting its status as a Dividend King (2.46% yield). While revenue growth is positive at 9.08% YoY, the sequential plateau (Q2 $23.74B to Q4 $24.56B) tempers near-term excitement. The implied price target from forward EPS ($17.48) and forward P/E suggests ~$314, indicating significant potential upside, but this is contingent on growth re-acceleration.
Risks & Conditions: The two biggest risks are a failure of the pipeline to compensate for Stelara's decline, leading to sustained growth deceleration, and valuation compression if its premium P/E contracts. This Hold rating would upgrade to a Buy if the forward P/E compressed below 16x (offering a clearer margin of safety) or if quarterly revenue growth re-accelerates above 10% on a sustainable basis. It would downgrade to a Sell if revenue growth turns negative or if the Stelara overhang causes EPS estimates to be revised down by more than 10%. Based on current data, the stock is fairly valued relative to its own history but carries a premium to its industry, justified by its exceptional financial quality.
Sign up to view all
JNJ 12-Month Price Forecast
JNJ is in a 'show me' phase. Its defensive attributes and financial quality are undeniable, making catastrophic loss unlikely. However, the stock lacks a clear near-term catalyst for significant outperformance as it navigates a major patent cliff. The base case of modest, single-digit returns is most probable. The stance would turn bullish on evidence of successful pipeline commercialization that reignites top-line growth, or if market volatility spikes, enhancing the appeal of its low-beta profile. It would turn bearish if the Stelara revenue gap widens faster than new products can fill it, threatening the earnings trajectory that supports its current multiple.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Johnson & Johnson's 12-month outlook, with a consensus price target around $300.68 and implied upside of +30.0% versus the current price.
Average Target
$300.68
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$185 - $301
Analyst target range
Analyst coverage for Johnson & Johnson is robust, with 15 analysts providing estimates, indicating strong institutional interest. The consensus sentiment leans bullish, as evidenced by recent institutional ratings from firms like RBC Capital ('Outperform'), HSBC ('Buy'), and Citigroup ('Buy'), though there are neutral stances from Barclays and JP Morgan. The average target price implied by earnings estimates is not explicitly stated, but the average estimated EPS for the forward period is $17.48, which, when applied to the forward PE of 17.96x, implies a price target of approximately $314, suggesting significant potential upside from the current price; however, the precise consensus price target and implied upside percentage are data not available in the provided dataset. The target range, inferred from revenue estimates, spans from a low of $128.23 billion to a high of $133.95 billion in estimated sales, indicating a relatively tight spread of about 4.5% around the consensus, which reflects high analyst conviction and lower uncertainty regarding the company's near-term revenue trajectory, a hallmark of a large, predictable blue-chip company.
Bulls vs Bears: JNJ Investment Factors
The evidence currently tilts slightly bullish, primarily due to JNJ's formidable financial fortress, reasonable valuation relative to its own history, and its defensive, low-volatility profile which is attractive in an uncertain macro environment. However, the bear case presents credible near-term challenges, most notably the plateauing sequential revenue growth and the looming patent expiration for Stelara, which has already manifested in recent sales declines. The single most important tension in the investment debate is the race between the company's strategic pipeline investments (like Firefly Bio) and the revenue erosion from its maturing blockbuster portfolio. The stock's performance over the next 12-24 months will hinge on whether new growth drivers can accelerate fast enough to offset the Stelara decline before investor patience wanes.
Bullish
- Exceptional Financial Strength & Cash Flow: The company generates massive annual free cash flow of $19.70 billion (TTM), enabling it to fund its dividend, strategic acquisitions like the recent $1 billion Firefly Bio deal, and share buybacks without straining its balance sheet. This is supported by a healthy debt-to-equity ratio of 0.59 and a stellar return on equity of 32.87%.
- Attractive Valuation Relative to History: The trailing P/E of 18.81x is well below its own 5-year highs (e.g., 36.20x in Q3 2024), suggesting the stock is not overvalued relative to its own history. The forward P/E of 17.96x indicates the market is pricing in stable, not decelerating, earnings growth.
- Strong Long-Term Price Momentum: The stock has significantly outperformed the S&P 500 over the past year, with a +51.52% gain versus the index's +24.99%. This robust uptrend, with the price sitting 64% of the way up its 52-week range, reflects strong investor confidence in its post-Kenvue transformation.
- Proactive Pipeline & Portfolio Management: Recent strategic moves, including the $1 billion acquisition of Firefly Bio to target 'undruggable' cancers and a successful Phase 2/3 trial for IMAAVY in a rare blood disorder, demonstrate active efforts to bolster its oncology and rare disease pipelines ahead of key patent expirations.
Bearish
- Revenue Growth Plateauing Sequentially: While Q4 2025 revenue grew 9.08% YoY, the sequential trend shows a plateau: Q2 ($23.74B), Q3 ($23.99B), Q4 ($24.56B). This deceleration raises questions about near-term growth momentum, especially as the company navigates the looming patent cliff for Stelara.
- Recent Short-Term Underperformance: The stock has underperformed the S&P 500 over the past 1 and 3 months, down -0.7% and -2.97% respectively, while the index gained +0.74% and +15.14%. This negative relative strength suggests a consolidation phase and potential loss of momentum.
- Gross Margin Volatility & Compression: Gross margin spiked to 86.37% in Q4 2025 from 69.56% in Q3, but this extreme volatility and the sharp QoQ compression from Q3's 69.56% indicate potential product mix shifts or one-time impacts that may not be sustainable, creating earnings uncertainty.
- High Valuation Premium to Industry: JNJ's trailing P/E of 18.81x trades at a premium to the broader Drug Manufacturers industry. While justified by its financial stability, this premium leaves the stock vulnerable to valuation compression if growth fails to meet elevated expectations or during sector rotations out of defensive names.
JNJ Technical Analysis
The stock is in a sustained long-term uptrend, evidenced by a robust 1-year price change of +51.52%, significantly outperforming the S&P 500's +24.99% gain. As of the latest close of $228.39, the price sits approximately 64% of the way up its 52-week range ($149.04 to $251.71), indicating it is trading in the upper half of its annual band, which reflects strong investor confidence but also suggests it is not at extreme overbought levels. Recent momentum, however, has diverged negatively from this long-term trend, with the stock down -0.7% over the past month and -2.97% over the past three months, starkly underperforming the S&P 500's gains of +0.74% and +15.14% over the same periods, signaling a notable short-term consolidation or pullback phase. Key technical support is anchored at the 52-week low of $149.04, while immediate resistance is at the 52-week high of $251.71; a decisive breakout above resistance would confirm a resumption of the primary bull trend, whereas a breakdown below recent lows near $220 could signal a deeper correction. The stock's exceptionally low beta of 0.256 indicates it is roughly 75% less volatile than the broader market, a characteristic that provides defensive stability but may also limit explosive upside moves during market rallies.
Beta
0.26
0.26x market volatility
Max Drawdown
-11.0%
Largest decline past year
52-Week Range
$150-$252
Price range past year
Annual Return
+54.4%
Cumulative gain past year
| Period | JNJ Return | S&P 500 |
|---|---|---|
| 1m | -1.3% | -0.2% |
| 3m | -1.7% | +14.0% |
| 6m | +11.3% | +7.8% |
| 1y | +54.4% | +25.3% |
| ytd | +11.5% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
JNJ Fundamental Analysis
Revenue growth remains positive but is showing signs of deceleration on a sequential basis; the most recent Q4 2025 revenue was $24.56 billion, representing a solid year-over-year growth of 9.08%, yet this follows a Q3 revenue of $23.99 billion and a Q2 revenue of $23.74 billion, indicating a plateauing trend in the latter half of the year. The company is highly profitable, with Q4 2025 net income of $5.12 billion and a robust gross margin of 86.37%, though this margin compressed from 69.56% in Q3, reflecting potential product mix shifts or one-time impacts; the net margin for the quarter was a healthy 20.83%, demonstrating strong bottom-line conversion. Financially, Johnson & Johnson is exceptionally strong, boasting a manageable debt-to-equity ratio of 0.59, a stellar return on equity of 32.87%, and substantial annual free cash flow of $19.70 billion (TTM), which provides ample liquidity to fund dividends, share repurchases, and strategic acquisitions like the recent $1 billion Firefly Bio deal without straining its balance sheet.
Quarterly Revenue
$24.6B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.86%
Latest Quarter
Free Cash Flow
$19.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is JNJ Overvalued?
Given the company's consistent profitability, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing twelve-month PE ratio stands at 18.81x, while the forward PE is slightly lower at 17.96x; this modest compression suggests the market anticipates stable, but not significantly accelerating, earnings growth in the near term. Compared to the broader Drug Manufacturers industry, JNJ's trailing PE of 18.81x trades at a premium; while a direct industry average is not provided in the data, the company's premium is typically justified by its superior financial stability, AAA-rated balance sheet, and status as a Dividend King, factors that command a lower risk premium. Historically, the current trailing PE of 18.81x sits well below its own 5-year highs seen in periods like Q3 2024 (36.20x) and is towards the lower end of its recent range, suggesting the stock is not overvalued relative to its own history and may offer a reasonable entry point given its defensive characteristics.
PE
18.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1502x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Johnson & Johnson's primary financial risk is not solvency—its balance sheet is rock-solid with a D/E of 0.59 and $19.7B in annual FCF—but rather earnings quality and growth sustainability. The extreme volatility in gross margin, which swung from 69.56% in Q3 to 86.37% in Q4, indicates potential one-time benefits or unstable product mix, making future profitability less predictable. Furthermore, revenue growth, while positive at 9.08% YoY in Q4, has plateaued sequentially over the last three quarters, signaling deceleration that could pressure the stock's premium valuation if it persists.
Market & Competitive Risks: The stock trades at a trailing P/E of 18.81x, a premium to its industry peers, making it susceptible to valuation compression if growth expectations are not met or during a market rotation away from defensive healthcare stocks into cyclicals. Its exceptionally low beta of 0.256, while a defensive strength, also means it may lag significantly during broad market rallies, as evidenced by its -18 percentage points of underperformance vs. the S&P 500 over the past three months. Competitively, the steep decline in Stelara sales highlights the constant pressure from patent expirations in the pharmaceutical industry, requiring continuous and successful R&D investment to maintain the top line.
Worst-Case Scenario: The most damaging scenario would involve a faster-than-expected decline in Stelara revenue coinciding with clinical setbacks in key pipeline assets like those acquired from Firefly Bio, leading to a significant earnings miss and a guidance cut. This could trigger multiple compression as the market reassesses JNJ's growth profile, potentially driving the stock down towards its 52-week low of $149.04. From the current price of ~$228, this represents a realistic maximum downside of approximately -35%. While the company's dividend and balance sheet would prevent a total collapse, such a drawdown would materially underperform the market and test the patience of long-term holders.
FAQ
The key risks are, in order of severity: 1) Pipeline/Patent Risk: The steep decline in blockbuster drug Stelara sales creates a near-term revenue gap that new products must fill; failure to do so would pressure growth. 2) Valuation Risk: Trading at a premium P/E (18.81x) to its industry, the stock is vulnerable to multiple compression if growth disappoints. 3) Operational Risk: Extreme quarterly gross margin volatility (from 69.56% to 86.37%) indicates earnings quality uncertainty. 4) Market Risk: Its low beta (0.256) is a defensive strength but means it may significantly lag during strong bull markets, as seen in its recent 3-month underperformance versus the S&P 500.
The 12-month forecast presents three scenarios. The base case (60% probability) sees the stock trading between $240 and $270, assuming steady execution and a stable P/E multiple. The bull case (25% probability) targets $280 to $315, driven by successful pipeline news and re-accelerated growth. The bear case (15% probability) warns of a drop to $190-$220 on faster Stelara erosion and valuation compression. The most likely outcome is the base case, anchored by the company's financial strength but capped by near-term growth headwinds. The average analyst EPS estimate of $17.48 implies a price target in the low $300s if the current forward multiple holds.
JNJ is fairly valued relative to its own history but trades at a premium to the broader Drug Manufacturers industry. Its trailing P/E of 18.81x is well below its 5-year high of 36.20x, suggesting it is not overvalued on that basis. However, the premium to peers implies the market is paying for its exceptional financial quality (AAA-balance sheet, $19.7B FCF) and defensive characteristics. The valuation is not demanding, but it also does not offer a clear margin of safety, pricing in stable execution of its growth transition plan.
JNJ is a good buy for a specific type of investor: those seeking a defensive, low-volatility holding with a reliable and growing dividend. For aggressive growth investors, it is less attractive due to its plateauing revenue growth and significant patent expiration overhang. The stock offers a reasonable valuation (forward P/E of 17.96x) and immense financial strength, but the near-term risk/reward is balanced, warranting a 'Hold' rating. It becomes a more compelling buy on a pullback towards $220 or if upcoming quarterly results show a re-acceleration in top-line growth.
JNJ is unequivocally a long-term investment. Its value proposition is built on decades of dividend growth, financial resilience, and the compounding effect of reinvested dividends. The current transitional period around patent expirations may create short-term volatility, but the company's strategy is designed for long-term portfolio renewal. Its low beta (0.256) and income focus make it poorly suited for short-term trading, which requires higher volatility and clearer near-term catalysts. A minimum holding period of 3-5 years is recommended to allow its strategic pipeline investments time to mature and contribute meaningfully to earnings.